Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

Vani Lakshminarayanan, Pamela Thompson, Margreet A Wolfert, Therese Buskas, Judy M Bradley, Latha B Pathangey, Cathy S Madsen, Peter A Cohen, Sandra J Gendler, Geert-Jan Boons

Research output: Contribution to journalArticleAcademicpeer-review


The mucin MUC1 is typically aberrantly glycosylated by epithelial cancer cells manifested by truncated O-linked saccharides. The resultant glycopeptide epitopes can bind cell surface major histocompatibility complex (MHC) molecules and are susceptible to recognition by cytotoxic T lymphocytes (CTLs), whereas aberrantly glycosylated MUC1 protein on the tumor cell surface can be bound by antibodies to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Efforts to elicit CTLs and IgG antibodies against cancer-expressed MUC1 have not been successful when nonglycosylated MUC1 sequences were used for vaccination, probably due to conformational dissimilarities. Immunizations with densely glycosylated MUC1 peptides have also been ineffective due to impaired susceptibility to antigen processing. Given the challenges to immuno-target tumor-associated MUC1, we have identified the minimum requirements to consistently induce CTLs and ADCC-mediating antibodies specific for the tumor form of MUC1 resulting in a therapeutic response in a mouse model of mammary cancer. The vaccine is composed of the immunoadjuvant Pam(3)CysSK(4), a peptide T(helper) epitope and an aberrantly glycosylated MUC1 peptide. Covalent linkage of the three components was essential for maximum efficacy. The vaccine produced CTLs, which recognized both glycosylated and nonglycosylated peptides, whereas a similar nonglycosylated vaccine gave CTLs which recognized only nonglycosylated peptide. Antibodies elicited by the glycosylated tripartite vaccine were significantly more lytic compared with the unglycosylated control. As a result, immunization with the glycosylated tripartite vaccine was superior in tumor prevention. Besides its own aptness as a clinical target, these studies of MUC1 are likely predictive of a covalent linking strategy applicable to many additional tumor-associated antigens.

Original languageEnglish
Pages (from-to)261-6
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number1
Publication statusPublished - 3 Jan 2012
Externally publishedYes


  • Amino Acid Sequence
  • Animals
  • Antibody-Dependent Cell Cytotoxicity
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Cytokines
  • Enzyme-Linked Immunosorbent Assay
  • Glycosylation
  • Humans
  • Immunity, Cellular
  • Immunity, Humoral
  • Mammary Tumor Virus, Mouse
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Molecular Sequence Data
  • Mucin-1
  • Neoplasms
  • T-Lymphocytes, Cytotoxic
  • Tumor Burden
  • Vaccines, Synthetic


Dive into the research topics of 'Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine'. Together they form a unique fingerprint.

Cite this